期刊文献+

男性性腺功能低减的雄激素替代治疗 被引量:3

Androgen Replacement Therapy for Hypogonadal Men
暂未订购
导出
摘要 男性性腺功能低减在男科临床常见 ,分为原发性和继发性两类 ,共同之处都在于雄激素不足。除病因治疗外 ,所有原发性性腺功能低减和没有生育力要求的继发性性腺功能低减病人都应采用雄激素替代治疗。目前可应用和正在研究中的雄激素制剂很多 。 Male hypogonadism is a group of syndromes in clinic andrology characterized by complete or partial androgen deficiency. It can be divided into primary and secondary hypogonadism. Besides the etiological treatment, androgen replacement therapy should be adopted in all patients of primary hypogonadism and patients of secondary hypogonadism who do not have the need of having a child. For patient's benefits, androgen should be used and selected properly as there are so many androgen preparation at present. Natl J Androl,2003,9(3):210-213
出处 《中华男科学杂志》 CAS CSCD 2003年第3期210-213,共4页 National Journal of Andrology
基金 江苏省 135医学重点人才项目资助 (RC2 0 0 2 0 76)
关键词 性腺功能低减 雄激素 男性 Hypogonadism Androgen Men
  • 相关文献

参考文献15

  • 1童建孙,崔毓桂,王兴海,狄福松,马鼎志,蔡瑞芬,冯婷,张桂元.TU治疗男性性腺功能低下的药代动力学和药效学研究[J].中华男科学杂志,2000,6(4):225-229. 被引量:9
  • 2李江源.中老年男子部分性雄激素缺乏综合征[J].生殖医学杂志,2000,9(3):182-186. 被引量:10
  • 3J.Lisa TENOVER.老年男性的睾酮替代疗法[J].中华男科学杂志,2001,7(3):141-146. 被引量:28
  • 4崔毓桂.老年男子的性和生殖[J].男科学报,1998,4(2):112-117. 被引量:2
  • 5Hellstrom WJC. The handbook of sexual dysfunction [ M ]. San Francisco: The American Society of Andrology, 1999.18-26, 39-42.
  • 6Yen SSC, Jaffe RB, Barbieri RL. Reproductive endocrinology:physiology, pathophysiology, and clinical management [ M ]. 4th Ed. England: Harcourt Publishers Limited, 1999. 622-668.
  • 7Kaiser FE. Erectile dysfunction in the aging man [J]. Med Clin North Am, 1999, 83(5):1267-1278.
  • 8Basaria S, Dobs AS. Risks versus benefits of testosterone therapy in elderly men[J]. Drugs Aging, 1999, 15(2) :131-142.
  • 9Winters SJ. Current status of testosterone replacement therapy in men [J]. Arch Faro Med, 1999, 8(3) :257-263.
  • 10Zitzmann M, Nieschlag E. Hormone substitution in male hypogonadism[J]. Mol Cell Endocrinol, 2000, 161(1-2) :73-88.

二级参考文献76

  • 1韩银发,王益鑫,吴裕伦,陈国武,陈斌,钱宪明,付桂霞,曹小蓉.雄激素替代治疗Klinefelter综合征[J].男性学杂志,1996,10(3):160-162. 被引量:5
  • 2张桂元 方圻.男性生殖内分泌病.现代内科学[M].北京:人民军医出版社,1995.2648-2681.
  • 3狄福松 张忠邦 等.Klinefelter’s综合征患者垂体-性腺内分泌功能研究[J].中华内分泌代谢杂志,1986,2(4):245-248.
  • 4[13]Goldray D, Weisman Y, Jaccard N et al. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH)[J]. J Clin Endocrinol Metab, 1993, 76:288~290.
  • 5[14]Behre HM, Kliesch S, Leifke E et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men [J]. J Clin Endocrinol Metab, 1997, 82:2386~2390.
  • 6[15]Leifke E, Korner HC, Link TM et al. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area, and paraspinal muscle area in hypogonadal men [J]. Eur J Endocrinol, 1998, 138:51~58.
  • 7[16]Katznelson L, Finkelstein JS, Schoenfeld DA et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism [J]. J Clin Endocrinol Metab, 1996,81:4358~4365.
  • 8[17]Reid IR, Wattie DJ, Evans MC et al. Testosterone therapy in gluco-corticoid treated men [J]. Arch Intern Med, 1996, 156:1173~1177.
  • 9[18]Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age [J]. J Clin Endocrinol Metab, 1999,84:1966~1972.
  • 10[19]Bhasin S, Storer TW, Berman N et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men [J]. J Clin Endocrinol Metab, 1997,82:407~413.

共引文献43

同被引文献38

  • 1李三祥,戴玉田.阴茎血管活性物质及其功能递质在勃起功能障碍发病中的作用[J].中华男科学杂志,2005,11(11):843-846. 被引量:9
  • 2Dudley RE, Kottayil SG, Palatchi O. Pharmaceutical composition and method for treating hypogonadism: US, 6503894 [ P/OL]. 2003-01-7 [ 2009-04-20]. http://www, patentstorm, us/patents/6503894, html.
  • 3韩可勤.医药应用数理统计[M].南京:东南大学出版社,2009:105.
  • 4Sasaki S, Imaeda T, Hayase Y, et al. A new class of potent nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists: Design and synthesis of 2-phenylimidazo(1,2-a)pyrimidin-5-ones[J]. Bioorg Med Chemis Letters, 2002, 12(16): 2073-2077.
  • 5Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial[J]. BJU International, 2002, 90(4): 427-432
  • 6Wen J, Davies N, Ledger R. Isocratic liquid chromatographic assay for monitoring the degradation of luteinizing hormone releasing hormone by extracts from the gastrointestinal tract of possums [J]. J Chromatography, 2002, 779(2): 221-227.
  • 7Kovacs M. Schally AV. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats[J]. Proc Natl Acad Sci USA, 2001,98(21):
  • 8Jakesz R. LHRH agonists[J]. Eur J Cancer, 2002, 38[Suppl 3]: S44.
  • 9Guemene D,Williams JB. LH responses to chicken luteinizing hormone-releasing hormone I and II in laying, incubating, and out of lay turkey hens [J]. Domestic Animal Endocrinology, 1999,17(1):1-15.
  • 10Coy D, Jennes L, Conn PM. Receptor-mediated uptake of GnRH agonist and antagonists by cultured gonadotropes: evidence for differnetial intracellular routing[J]. Peptides, 1986,7(3):459-463.

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部